Published Date: 26 Apr 2023
According to researchers from the Karolinska Institutet, patients with Crohn's disease and IBD have an elevated risk of developing lymphoma, and this risk has grown over the past few years.
Read Full NewsNew phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.
Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.
1.
Clinical trial is testing whether heavy lifting could combat cancer side effects
2.
The most precise research tools for the deadliest blood cancer have been developed.
3.
Survival improved with lobectomy, segmentectomy in early non-small cell lung cancer
4.
Recent research suggests that vitamin supplements may increase the risk of developing cancer.
5.
Taking vitamin D daily decreased cancer mortality, according to a study.
1.
Molecular Matching for Individualized Blood-Disorder Therapy
2.
Cemiplimab: A Revolutionary Drug For Treating Cancer
3.
Emerging Therapies Through Engineered Blood Cell Manufacturing Platforms
4.
Care Coordination in Chronic Anemia: Mechanisms, Clinical Implications, and Emerging Strategies
5.
From Bruises to Blood Clots: Everything You Need to Know about Hematoma
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
Thromboprophylaxis In Medical Settings
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
5.
When Unexplained Bruising May Require Blood Testing
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation